Quick Summary:
In an ever-transforming global healthcare sector, staying ahead of pivotal developments is crucial. Substantial growth is forecasted in the global TNF Inhibitors market, predicted to reach an impressive sum of US$106.9 Billion by 2030. This comprehensive market research report, with its exhaustive exploration of industry trends, key market players, and emerging opportunities, equips business leaders with the knowledge and understanding required to leverage this growth, and draw strategic insights for future decisions.
The facts and figures contained in this report will enable executives not only to gauge the current market standing in major economies like the United States and China, but also obtain a high-level view of the potential held by less explored markets such as Japan and Canada. Focused competitor analysis will further provide a profound understanding of the key drivers within the TNF Inhibitors market, aiding companies in making calculated, strategic moves in this progressively competitive environment.
Global TNF Inhibitors Market to Reach $106.9 Billion by 2030
The global market for TNF Inhibitors estimated at US$64 Billion in the year 2022, is projected to reach a revised size of US$106.9 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2022-2030. Rheumatoid Arthritis, one of the segments analyzed in the report, is projected to record 8.5% CAGR and reach US$22.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Psoriasis segment is readjusted to a revised 6.7% CAGR for the next 8-year period.
The U.S. Market is Estimated at $17.4 Billion, While China is Forecast to Grow at 10.9% CAGR
The TNF Inhibitors market in the U.S. is estimated at US$17.4 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$24.7 Billion by the year 2030 trailing a CAGR of 10.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.4% and 6.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.Select Competitors (Total 41 Featured) -
- AbbVie Inc.
- Amgen Inc.
- Biocad Biopharmaceutical Co.
- Boehringer Ingelheim Pharmaceuticals, Inc.
- EPIRUS Biopharmaceuticals, Inc.
- Innovent Biologics, Inc.
- Janssen Biotech, Inc.
- Johnson & Johnson Services, Inc.
- Merck & co., Inc.
- Novartis International AG
- Pfizer, Inc.
- Shanghai Henlius Biotech, Inc.
- UCB S.A.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for TNF Inhibitors?
What is the growth rate of the Global Market for TNF Inhibitors?
What is the forecasted size of the Global Market for TNF Inhibitors?
Who are the key companies in the Global Market for TNF Inhibitors?
| Report Attribute | Details |
|---|---|
| No. of Pages | 194 |
| Published | December 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 64 Billion |
| Forecasted Market Value ( USD | $ 106.9 Billion |
| Compound Annual Growth Rate | 6.6% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- AbbVie Inc.
- Amgen Inc.
- Biocad Biopharmaceutical Co.
- Boehringer Ingelheim Pharmaceuticals, Inc.
- EPIRUS Biopharmaceuticals, Inc.
- Innovent Biologics, Inc.
- Janssen Biotech, Inc.
- Johnson & Johnson Services, Inc.
- Merck & co., Inc.
- Novartis International AG
- Pfizer, Inc.
- Shanghai Henlius Biotech, Inc.
- UCB S.A.
